Eli Lilly Total Long-Term Assets 2010-2024 | LLY

Eli Lilly total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Eli Lilly total long-term assets for the quarter ending September 30, 2024 were $44.192B, a 26.59% increase year-over-year.
  • Eli Lilly total long-term assets for 2023 were $38.279B, a 21.69% increase from 2022.
  • Eli Lilly total long-term assets for 2022 were $31.455B, a 3.63% increase from 2021.
  • Eli Lilly total long-term assets for 2021 were $30.354B, a 4.05% increase from 2020.
Eli Lilly Annual Total Long-Term Assets
(Millions of US $)
2023 $38,279
2022 $31,455
2021 $30,354
2020 $29,171
2019 $25,577
2018 $23,359
2017 $25,779
2016 $23,705
2015 $22,995
2014 $24,379
2013 $22,144
2012 $21,360
2011 $19,412
2010 $16,161
2009 $14,974
Eli Lilly Quarterly Total Long-Term Assets
(Millions of US $)
2024-09-30 $44,192
2024-06-30 $41,671
2024-03-31 $38,755
2023-12-31 $38,279
2023-09-30 $34,909
2023-06-30 $33,482
2023-03-31 $32,352
2022-12-31 $31,455
2022-09-30 $29,822
2022-06-30 $29,948
2022-03-31 $29,955
2021-12-31 $30,354
2021-09-30 $30,379
2021-06-30 $30,514
2021-03-31 $30,234
2020-12-31 $29,171
2020-09-30 $27,706
2020-06-30 $27,385
2020-03-31 $27,109
2019-12-31 $25,577
2019-09-30 $25,231
2019-06-30 $25,212
2019-03-31 $25,409
2018-12-31 $23,359
2018-09-30 $23,939
2018-06-30 $24,027
2018-03-31 $28,094
2017-12-31 $25,779
2017-09-30 $25,582
2017-06-30 $25,200
2017-03-31 $24,648
2016-12-31 $23,705
2016-09-30 $24,204
2016-06-30 $23,498
2016-03-31 $22,977
2015-12-31 $22,995
2015-09-30 $23,738
2015-06-30 $23,691
2015-03-31 $23,911
2014-12-31 $24,379
2014-09-30 $22,538
2014-06-30 $21,862
2014-03-31 $21,718
2013-12-31 $22,144
2013-09-30 $20,763
2013-06-30 $20,587
2013-03-31 $19,974
2012-12-31 $21,360
2012-09-30 $20,282
2012-06-30 $19,505
2012-03-31 $19,636
2011-12-31 $19,412
2011-09-30 $18,470
2011-06-30 $17,829
2011-03-31 $16,341
2010-12-31 $16,161
2010-09-30 $15,720
2010-06-30 $15,257
2010-03-31 $14,945
2009-12-31 $14,974
2009-09-30 $15,318
2009-06-30 $15,996
2009-03-31 $16,336
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94